STOCK TITAN

Tenon Medical, Inc. - TNON STOCK NEWS

Welcome to our dedicated page for Tenon Medical news (Ticker: TNON), a resource for investors and traders seeking the latest updates and insights on Tenon Medical stock.

Tenon Medical, Inc. (TNON) delivers innovative solutions for sacroiliac joint disorders through its Catamaran™ System. This page provides authorized updates on clinical advancements, regulatory milestones, and strategic developments directly from the company and verified sources.

Investors and medical professionals will find comprehensive coverage of FDA clearances, peer-reviewed study results, and partnership announcements. Our curated news collection features earnings reports, product launch details, and analysis of market expansion efforts in minimally invasive spine technology.

Key updates include progress in post-market clinical studies, intellectual property developments, and educational initiatives for surgeons. All content undergoes strict verification to ensure alignment with financial disclosure regulations and medical accuracy standards.

Bookmark this page for real-time updates on TNON's pioneering work in SI joint fusion technology. For direct access to corporate filings and investor resources, visit the official Tenon Medical website through our verified links.

Rhea-AI Summary

Tenon Medical (NASDAQ:TNON) reported significant growth in its Q1 2024 financial results, showcasing a 66% year-over-year revenue increase to $719,000, driven by a 42% rise in Catamaran System surgical procedures.

The company achieved a gross profit of $470,000, marking a stark improvement from a gross loss of ($47,000) in Q1 2023, with a stable gross margin of 65%.

Notable developments include positive fusion results from a post-market study of the Catamaran SI Joint Fusion System and the receipt of a U.S. patent allowance for its Catamaran implant.

The company reduced its operating losses to $3.5 million, down from $4.9 million in Q1 2023, and ended the quarter with $4.4 million in cash and cash equivalents.

Additionally, Tenon retired $1.25 million in debt through a $2.6 million Series A Preferred Stock financing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.22%
Tags
-
Rhea-AI Summary

Tenon Medical, Inc. will announce its first quarter 2024 financial results on May 14, 2024, after market close. The company will host a conference call to discuss the results in detail, followed by a Q&A session with analysts. Investors can access the call via dial-in or webcast and listen to the playback on the Investor Relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.44%
Tags
-
Rhea-AI Summary
Tenon Medical, Inc. appoints Kristine Jacques, an experienced medical devices industry executive, to its Board of Directors. Ms. Jacques brings over 35 years of expertise in global commercialization, marketing, and product management. Her appointment aims to enhance Tenon's commercialization strategy for its Catamaran System and SI technologies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.56%
Tags
management
Rhea-AI Summary
Tenon Medical, Inc. announces significant progress in a post-market study for sacroiliac joint disorders using the Catamaran SI Joint Fusion System. Preliminary results show robust fusion at 12 months post-procedure, along with improvements in pain scores and high patient satisfaction ratings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.05%
Tags
none
-
Rhea-AI Summary
Tenon Medical, Inc. (TNON) reports impressive financial results for Q4 2023 and full year 2023 with significant revenue growth, positive gross profit margins, and increased surgical procedures. The company's Catamaran SI Joint Fusion System was featured in physician training programs, leading to a 312% increase in procedures. Tenon also raised capital through Series A Preferred Stock issuance and debt repayment. Despite the strong performance, operating losses decreased, and the company expects additional losses in the future.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.76%
Tags
-
Rhea-AI Summary
Tenon Medical, Inc. (TNON) to release financial results for Q4 and full year 2023 on March 12, 2024. Conference call scheduled for analysts and investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.36%
Tags
Rhea-AI Summary
Tenon Medical, Inc. received a Notice of Allowance from the USPTO for its Catamaran® SI Joint implant, enhancing its patent portfolio. The company aims to provide innovative products for patients with sacroiliac joint disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.42%
Tags
none
-
Rhea-AI Summary
Tenon Medical, Inc. raises approximately $2.6 million in gross proceeds through a private placement of Series A Preferred Stock and warrants. The company also retires $1.25 million in secured debt. The funds will be used for growth investments, working capital, and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.63%
Tags
none
-
Rhea-AI Summary
Tenon Medical, Inc. (NASDAQ: TNON) adjourns Special Meeting of Stockholders to January 30, 2024, to obtain votes on Proposal 2, approval of an amendment of the Certificate of Incorporation. Stockholders can vote using touch-tone phone, internet, or mail.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.97%
Tags
none
Rhea-AI Summary
Tenon Medical, Inc. (NASDAQ: TNON) adjourns Special Meeting of Stockholders to January 8, 2024, to obtain votes on Proposal 2, approval of an amendment of the Certificate of Incorporation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.16%
Tags
none
Tenon Medical, Inc.

Nasdaq:TNON

TNON Rankings

TNON Stock Data

5.63M
6.18M
1.63%
4.19%
5.3%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
LOS GATOS